Outcomes of Patients With Revised Stage I Clear Cell Sarcoma of Kidney Treated in National Wilms Tumor Studies 1-5
| Autor: | Nita L. Seibel, Elizabeth J. Perlman, Jeffrey S. Dome, Michael L. Ritchey, John A. Kalapurakal, Paul E. Grundy |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Clear-cell sarcoma of the kidney Adolescent medicine.medical_treatment Nephrectomy Disease-Free Survival Young Adult Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Child Survival rate Neoplasm Staging Chemotherapy Radiation Radiotherapy business.industry Infant Neoplasms Second Primary Radiotherapy Dosage Wilms' tumor medicine.disease Combined Modality Therapy Kidney Neoplasms Surgery Survival Rate Radiation therapy Regimen Treatment Outcome Oncology Child Preschool Female Sarcoma Clear Cell Sarcoma Radiology business Follow-Up Studies |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 85:428-431 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2012.04.023 |
| Popis: | Purpose To report the clinical outcomes of children with revised stage I clear cell sarcoma of the kidney (CCSK) using the National Wilms Tumor Study Group (NWTS)-5 staging criteria after multimodality treatment on NWTS 1-5 protocols. Methods and Materials All CCSK patients enrolled in the National Wilms Tumor Study Group protocols had their pathology slides reviewed, and only those determined to have revised stage I tumors according to the NWTS-5 staging criteria were included in the present analysis. All patients were treated with multimodality therapy according to the NWTS 1-5 protocols. Results A total of 53 children were identified as having stage I CCSK. All patients underwent primary surgery with radical nephrectomy. The chemotherapy regimens used were as follows: regimen A, C, F, or EE in 4 children (8%); regimen DD or DD4A in 33 children (62%); regimen J in 4 children (8%); and regimen I in 12 children (22%). Forty-six patients (87%) received flank radiation therapy (RT). Seven children (13%) did not receive flank RT. The median delay between surgery and the initiation of RT was 9 days (range, 3-61). The median RT dose was 10.8 Gy (range, 10-36). The flank RT doses were as follows: 10.5 or 10.8 Gy in 25 patients (47%), 11-19.9 Gy in 2 patients (4%), 20-29.9 Gy in 9 patients (17%), and 30-40 Gy in 10 patients (19%). The median follow-up for the entire group was 17 years (range, 2-36). The relapse-free and cancer-specific survival rate was 100% at the last follow-up examination. Conclusions The present results have demonstrated that children with revised stage I CCSK using the NWTS-5 staging criteria have excellent survival rates despite the use of varying RT doses and chemotherapy regimens in the NWTS 1-5 protocols. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|